苯达莫司汀
美罗华
医学
氟达拉滨
冷凝集素病
内科学
胃肠病学
中性粒细胞减少症
外科
淋巴瘤
化疗
环磷酰胺
自身免疫性溶血性贫血
贫血
作者
Sigbjørn Berentsen,Ulla Randen,Markku Oksman,Henrik Birgens,Tor Henrik Anderson Tvedt,Jakob Dalgaard,Eivind Galteland,Einar Haukås,Robert Brudevold,Jon Hjalmar Sørbø,Inger Anne Næss,Agnieszka Małecka,Geir E. Tjønnfjord
出处
期刊:Blood
[Elsevier BV]
日期:2017-05-23
卷期号:130 (4): 537-541
被引量:133
标识
DOI:10.1182/blood-2017-04-778175
摘要
Key Points Bendamustine-rituximab therapy results in high overall and CR rates with sustained remissions in CAD. Bendamustine plus rituximab may be considered in first line for most patients with CAD requiring therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI